Litcius/Paper detail

Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees

Minghui Wu, Siying Wu, Gaobo Wang, Wengang Liu, Lok Ting Chu, Tianyi Jiang, Hoi Kwan Kwong, Hiu Lam Chow, Iris Wai Sum Li, Ting‐Hsuan Chen

2022Science Advances29 citationsDOIOpen Access PDF

Abstract

Various COVID-19 vaccines are currently deployed, but their immunization varies and decays with time. Antibody level is a potent correlate to immune protection, but its quantitation relies on intensive laboratory techniques. Here, we report a decentralized, instrument-free microfluidic device that directly visualizes SARS-CoV-2 antibody levels. Magnetic microparticles (MMPs) and polystyrene microparticles (PMPs) can bind to SARS-CoV-2 antibodies simultaneously. In a microfluidic chip, this binding reduces the incidence of free PMPs escaping from magnetic separation and shortens PMP accumulation length at a particle dam. This visual quantitative result enables use in either sensitive mode [limit of detection (LOD): 13.3 ng/ml; sample-to-answer time: 70 min] or rapid mode (LOD: 57.8 ng/ml; sample-to-answer time: 20 min) and closely agrees with the gold standard enzyme-linked immunosorbent assay. Trials on 91 vaccinees revealed higher antibody levels in mRNA vaccinees than in inactivated vaccinees and their decay in 45 days, demonstrating the need for point-of-care devices to monitor immune protection.

Topics & Concepts

AntibodyVirologyCoronavirus disease 2019 (COVID-19)Detection limitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunizationMicrofluidicsImmune system2019-20 coronavirus outbreakImmunologyChemistryBiologyMedicineNanotechnologyMaterials scienceChromatographyOutbreakDiseaseInfectious disease (medical specialty)PathologySARS-CoV-2 detection and testingBiosensors and Analytical DetectionSARS-CoV-2 and COVID-19 Research
Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees | Litcius